Fairness opinions › Acquirers
Johnson & Johnson: healthcare acquisitions with fairness opinions
4 public-company targets, 2010-2024, $48B combined enterprise value. The multiples Johnson & Johnson paid and the banker analyses behind each target board's recommendation.
Deals
4
Median EV / EBITDA paid
39.5x
Median EV / revenue paid
8.46x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2024-04-05 | Shockwave Medical | Johnson & Johnson | Medical Devices and Supplies | $13B | 58.5x | 13.80x | 11.3%–12.8% | Perella Weinberg Partners |
| 2022-11-01 | Abiomed | Johnson & Johnson | Medical Devices and Supplies | $17B | 55.9x | 12.83x | 11.5%–13.0% | Goldman Sachs |
| 2011-04-27 | Synthes | Johnson & Johnson | Medical Devices and Supplies | $17B | 9.6x | 4.09x | 8.5%–10.5% | Credit Suisse |
| 2010-07-12 | Micrus Endovascular | Johnson & Johnson | Medical Devices and Supplies | $397M | 23.1x | 3.70x | 11.0%–13.0% | Lazard |